ONCOLOGY NATION

A SKIPTA COMMUNITY

Oncology Nation by the Numbers

Engage with verified HCPs in Skipta’s online communities when they are focused on learning and collaborating with other NPIs within their own specialty or interest area.

Verified HCPs Reached

What are HCPs talking about?

Slide 8

Patient Care

Expanding Horizons in Multiple Myeloma: CD38 Antibodies in Transplant-Eligible Patients

CD38 antibodies are now used in all pts, transplant eligible and ineligible. Makes the role of transplant more unclear given added benefits of darzalex in pts eligible for transplant.

Slide 2

Patient Care

"Not Even My Husband Knows That I Have This [Breast Cancer]": Survivors' Experiences in Accessing, Navigating and Coping With Treatment

This is an important issue; I have a few patients who want to hide their Dx for whatever reasons. A couple times I had to go to CMF to ensure low risk of alopecia. I think some women are afraid that their husbands will leave them if they know that they are sick

Slide 1

Prescribing Decisions

CAR T-cell therapy in heavily pretreated patients with RRMM

Depends upon the patient's comorbidities, prior therapies used including proteosome inhibitors, immunomodulatory agents, anti-CD38 antibodies, side effects from prior therapies, triple refractory versus penta refractory, performance status, high risk by genomic profiling, social support and ability to travel and stay around tertiary centers if they qualify for CAR-T cell therapy or willing to be admitted to the hospital for starting bi specific antibody therapy.

Slide 3

Patient Care

Advances in SCLC: Combining immunotherapy and chemotherapy to enhance patient outcomes

There is a significant unmet need when it comes to immunotherapy in SCLC as well as many malignancies. Currently we treat everyone homogeneously when we now that not all SCLC is created equally. Some people benefit from the therapy while others only get toxicity. Once we establish reliable biomarkers/phenotypes that identify whom we can help and who gains no benefit from the treatment that will be a real step in the right direction. I'm optimistic that we will get there and I hope it is soon.

Slide 4

Patient Care

Advances in SCLC: Combining immunotherapy and chemotherapy to enhance patient outcomes

Currently, I use immunotherapy as maintenance durvalumab after concurrent chemo RT in limited stage small cell cancer, and incorporate immunotherapy with Chemo then maintenance immunotherapy for extensive stage. This is for all comers, but hopefully precision medicine will help Tailor immunotherapy better in the future.

Slide 5

Patient Care

CD19-directed CAR T-cell therapy offers new hope for relapsed/refractory B-cell lymphoma patients after two prior lines of systemic therapy

I evaluate the efficacy based on clinical trial results. These patients do not have great options, but now with the advent of cellular therapy, including CAR-T these patients can enjoy good duration of response and disease control. Not sure if this really is curative in most people, but in my opinion, CAR-T is standard of care after two prior lines of therapy.

Slide 7

Patient Care

Evolving the standard: CAR T-cell therapy in second-line treatment for relapsed/refractory large B-cell lymphoma

For DLBCL the goal should be cure in fit patients, however the likelihood of cure decreases with subsequent relapses and primary refractory or high risk (ie double hit) have worse prognoses. I think the data showing survival benefits for CART in early relapsed disease after initial therapy favor CART over high dose chemo and autologous transplant. We are becoming better at managing side effects such as CRS and ICANS as well as infections so I think the benefits outweigh the risks.

ONCOLOGY NATION

A SKIPTA COMMUNITY

Oncology Nation by the Numbers

What are HCPs talking about?

Make your brand the heart of key HCP conversations, with customized, targeted brand messaging.